As seen in this article, “On June 14, 2013, the New Jersey Appellate Division affirmed the grant of summary judgment in favor of firm client Novartis Pharmaceuticals Corporation on the grounds that Virginia’s statute of limitations barred the case in its entirety. Irby v. Novartis Pharm. Corp., No. A-4871-11T3 (N.J. Super. Ct. App. Div. June 14, 2013). Novartis was represented in Irby by DRI members Joe G. Hollingsworth, Katharine R. Latimer, and Rebecca A. Womeldorf of Hollingsworth LLP in Washington, D.C., and Beth S. Rose of Sills Cummis & Gross P.C. in Newark, New Jersey. Mr. Irby alleged in a lawsuit filed in New Jersey that Novartis’s drug Zometa caused him to develop osteonecrosis of the jaw. Oncologists—and even plaintiff’s experts in this litigation—widely acknowledge that Zometa has revolutionized the treatment of the ravaging and painful symptoms of cancer, especially in patients whose cancer has metastasized to their bones.”
